(Q37799365)

23 August 2017

title

New evidence for nicotinic acid treatment to reduce atherosclerosis (English)

1 reference

23 August 2017

1 reference

Giorgio Luciano Viviani

Giorgio Luciano Viviani

4

0 references

Franco Dallegri

Franco Dallegri

3

0 references

Fabrizio Montecucco

Fabrizio Montecucco

1

0 references

Alessandra Quercioli

2

Alessandra Quercioli

1 reference

23 August 2017

5

François Mach

1 reference

23 August 2017

publication date

1 October 2010

1 reference

Expert Review of Cardiovascular Therapy

23 August 2017

published in

1 reference

23 August 2017

volume

8

1 reference

23 August 2017

issue

10

1 reference

23 August 2017

page(s)

1457-1467

1 reference

Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Influence of nicotinic acid on serum cholesterol in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Photoprotective effects of nicotinamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Safety of high-dose nicotinamide: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Nicotinic acid: pharmacological effects and mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Molecular identification of high and low affinity receptors for nicotinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Nicotinic acid receptor subtypes and their ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

New perspectives on the use of niacin in the treatment of lipid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Effects of colestipol-niacin therapy on human femoral atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Extended-release niacin or ezetimibe and carotid intima-media thickness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment dura

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Nicotinic acid and the prevention of coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Niacin and cholesterol: role in cardiovascular disease (review).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Mechanism of action of niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Effects of extended-release niacin on lipoprotein subclass distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Role of C-reactive protein in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Niacin extended-release/lovastatin: combination therapy for lipid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Increased total and high-molecular weight adiponectin after extended-release niacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

The SLIM Study: Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Niacin inhibits surface expression of ATP synthase beta chain in HepG2 cells: implications for raising HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Molecular identification of nicotinic acid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Niacin stimulates adiponectin secretion through the GPR109A receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Langerhans cells release prostaglandin D2 in response to nicotinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: an in vitro model of the niacin flush

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Neutrophil apoptosis mediated by nicotinic acid receptors (GPR109A)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

Effects of niacin on cell adhesion and early atherogenesis: biochemical and functional findings in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.116

21 January 2018

Identifiers

DOI

10.1586/ERC.10.116

1 reference

23 August 2017

1 reference